Medicine and Dentistry
Neoplasm
100%
Breast Cancer
84%
Breast Carcinoma
62%
Metastatic Carcinoma
37%
Lobular Carcinoma in Situ
37%
Diseases
32%
Carcinoma
29%
Lymph Node
27%
Lobular Carcinoma
27%
Neoadjuvant Chemotherapy
26%
Immunohistochemistry
26%
Malignant Neoplasm
26%
Lymph Node Metastasis
24%
Axillary Lymph Node
23%
Biopsy Technique
23%
Needle Biopsy
22%
Estrogen Receptor
18%
Diagnosis
17%
Tumor Cell
17%
Intraductal Carcinoma
15%
Recurrent Disease
15%
Cancer
14%
Sentinel Lymph Node
14%
Breast Lesion
14%
Overall Survival
13%
Papillary Carcinoma
12%
Mammography
12%
Uvomorulin
12%
Biological Marker
12%
Breast Tumor
12%
Transcription Factor GATA 3
12%
Carcinoma in Situ
12%
Hyperplasia
11%
Progesterone Receptor
11%
Papilloma
10%
Cytokeratin
10%
Pathologist
10%
Invasive Carcinoma
10%
Differential Diagnosis
9%
Triple Negative Breast Cancer
9%
Breast Tissue
9%
Fine-Needle Aspiration
8%
Echography
8%
Mastectomy
8%
Disease Free Survival
8%
Atypical Hyperplasia
8%
Male Breast Cancer
8%
Male Breast
8%
Krukenberg Tumor
8%
Protein P53
8%
Keyphrases
Breast Carcinoma
40%
Tumor
34%
Invasive Lobular Carcinoma
25%
Breast Cancer
24%
Breast
21%
Lobular Carcinoma in Situ
18%
Neoadjuvant Chemotherapy
16%
Breast Cancer Patients
13%
Tumor Cells
13%
Prognostic Significance
12%
Ductal Carcinoma in Situ
12%
Histopathological Features
11%
Pathological Complete Response
11%
Pathologic
10%
Axillary Lymph Node Metastasis
10%
Immunohistochemistry
10%
Metastasis
9%
Lymph Node Positive
9%
Sentinel Lymph Node
9%
Overall Survival
9%
E-cadherin
8%
Progesterone Receptor
8%
Occult
8%
Intracystic Papillary Carcinoma
8%
TRPS1
8%
Early Breast Cancer
8%
GATA3
8%
Allelic Loss
8%
Mammary Carcinoma
8%
Sonography
8%
Disease-free Survival
8%
Axillary Lymph Node
8%
Mammography
7%
Immunohistochemical Analysis
7%
Lymph Node
7%
In Situ Carcinoma
7%
Tumor Size
7%
Occult Metastasis
6%
Estrogen Receptor
6%
Cytokeratin
6%
Breast Reconstruction
6%
Neoplasms
6%
Clinical Outcomes
6%
Chemotherapy
6%
Ultrasound
6%
Mastectomy
6%
Loss of Heterozygosity
6%
Human Epidermal Growth Factor Receptor 2 (HER2)
6%
Pathological Findings
6%
Hematoxylin
6%